推薦產品
等級
pharmaceutical primary standard
API 家族
fluorometholone
製造商/商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]4(C)C=CC(=O)C=C14
InChI
1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
InChI 密鑰
FAOZLTXFLGPHNG-KNAQIMQKSA-N
基因資訊
human ... NR3C1(2908)
尋找類似的產品? 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Fluorometholone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Fluorometholone Acetate
- Fluorometholone Ophthalmic Suspension
- Hydrocortisone Hemisuccinate
- Hydrocortisone Sodium Succinate for Injection
- Methylprednisolone Hemisuccinate
- Methylprednisolone Sodium Succinate for Injection
生化/生理作用
Clinically significant in allergic conjunctivitis and as anti-inflammatory following cataract surgery.
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險分類
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
The British journal of ophthalmology, 95(11), 1531-1533 (2011-02-08)
Although fluorometholone (FML) is considered a steroid of minimal ocular penetration, reports in children have shown dose-dependent intraocular pressure (IOP) rise. The authors aimed to assess whether reducing regimens of FML for paediatric ocular surface disease have sustained clinically significant
Tear menisci after laser in situ keratomileusis with mechanical microkeratome and femtosecond laser.
Investigative ophthalmology & visual science, 55(9), 5806-5812 (2014-08-26)
To investigate the effect on tear menisci after laser in situ keratomileusis (LASIK) with flap creation by either microkeratome or femtosecond laser. Sixty eyes of 30 myopes were analyzed. Fifteen patients underwent LASIK with Moria II microkeratome, and the other
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 252(6), 963-968 (2014-05-07)
To evaluate the feasibility of partial lamellar keratoplasty (LK) for treatment of peripheral corneal disease (PCD) using a graft from the corneoscleral rim preserved in glycerin. Patients who underwent LK for PCD at Shandong Eye Hospital from January 2006 to
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 252(6), 983-987 (2014-03-29)
To analyze the efficacy of selective laser trabeculoplasty (SLT) on silicone oil-induced secondary glaucoma in terms of intraocular pressure (IOP). 42 patients (42 eyes) with silicone oil-induced secondary glaucoma were selected, and SLT was performed with 360° of the trabecular
JAMA ophthalmology, 133(1), 51-59 (2014-10-17)
Wavefront-guided (WFG) and wavefront-optimized (WFO) platforms for refractive surgery are designed for improved visual outcomes. It is unclear which treatment profile is superior for patients undergoing photorefractive keratectomy (PRK). To compare the safety, efficacy, predictability, stability, and higher-order aberrations in
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務